Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 410

1.

Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.

Warnat P, Oberthuer A, Fischer M, Westermann F, Eils R, Brors B.

BMC Cancer. 2007 May 25;7:89. Review.

2.

TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.

Shimada H, Nakagawa A, Peters J, Wang H, Wakamatsu PK, Lukens JN, Matthay KK, Siegel SE, Seeger RC.

Cancer. 2004 Oct 15;101(8):1873-81.

3.

MYCN protein expression as a predictor of neuroblastoma prognosis.

Chan HS, Gallie BL, DeBoer G, Haddad G, Ikegaki N, Dimitroulakos J, Yeger H, Ling V.

Clin Cancer Res. 1997 Oct;3(10):1699-706.

4.

Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.

Raschellà G, Cesi V, Amendola R, Negroni A, Tanno B, Altavista P, Tonini GP, De Bernardi B, Calabretta B.

Cancer Res. 1999 Jul 15;59(14):3365-8.

5.

Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome.

Fischer M, Oberthuer A, Brors B, Kahlert Y, Skowron M, Voth H, Warnat P, Ernestus K, Hero B, Berthold F.

Clin Cancer Res. 2006 Sep 1;12(17):5118-28.

6.

Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma.

Manohar CF, Salwen HR, Brodeur GM, Cohn SL.

Genes Chromosomes Cancer. 1995 Nov;14(3):196-203.

PMID:
8589036
7.

Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q.

McArdle L, McDermott M, Purcell R, Grehan D, O'Meara A, Breatnach F, Catchpoole D, Culhane AC, Jeffery I, Gallagher WM, Stallings RL.

Carcinogenesis. 2004 Sep;25(9):1599-609. Epub 2004 Apr 16. Review.

PMID:
15090470
8.

Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.

George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L, Brodeur GM, Castleberry RP, Look AT.

J Clin Oncol. 2005 Sep 20;23(27):6466-73. Epub 2005 Aug 22.

PMID:
16116152
9.

Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.

Goto S, Umehara S, Gerbing RB, Stram DO, Brodeur GM, Seeger RC, Lukens JN, Matthay KK, Shimada H.

Cancer. 2001 Nov 15;92(10):2699-708.

PMID:
11745206
10.

The high level of hCDC10 gene expression in neuroblastoma may be associated with favorable characteristics of the tumor.

Nagata T, Takahashi Y, Asai S, Ishii Y, Mugishima H, Suzuki T, Chin M, Harada K, Koshinaga S, Ishikawa K.

J Surg Res. 2000 Aug;92(2):267-75.

PMID:
10896833
11.

Gene expression profiling and identification of novel prognostic marker genes in neuroblastoma.

Takita J, Ishii M, Tsutsumi S, Tanaka Y, Kato K, Toyoda Y, Hanada R, Yamamoto K, Hayashi Y, Aburatani H.

Genes Chromosomes Cancer. 2004 Jun;40(2):120-32.

PMID:
15101045
12.

MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.

Spitz R, Hero B, Skowron M, Ernestus K, Berthold F.

Eur J Cancer. 2004 Dec;40(18):2753-9.

PMID:
15571958
13.

Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease.

Oberthuer A, Warnat P, Kahlert Y, Westermann F, Spitz R, Brors B, Hero B, Eils R, Schwab M, Berthold F, Fischer M.

Cancer Lett. 2007 Jun 8;250(2):250-67. Epub 2006 Nov 28.

PMID:
17126996
14.

Gene expression profiling of primary cutaneous melanoma and clinical outcome.

Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A; Melanoma Group of the European Organization for Research and Treatment of Cancer.

J Natl Cancer Inst. 2006 Apr 5;98(7):472-82.

PMID:
16595783
15.

Expression of mRNA for the neurotrophin receptor trkC in neuroblastomas with favourable tumour stage and good prognosis.

Rydén M, Sehgal R, Dominici C, Schilling FH, Ibáñez CF, Kogner P.

Br J Cancer. 1996 Sep;74(5):773-9.

16.
17.

Traditional and emerging molecular markers in neuroblastoma prognosis: the good, the bad and the ugly.

Poremba C, Hero B, Goertz HG, Scheel C, Wai D, Schaefer KL, Christiansen H, Berthold F, Juergens H, Boecker W, Dockhorn-Dworniczak B.

Klin Padiatr. 2001 Jul-Aug;213(4):186-90.

PMID:
11528552
18.

Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis.

Shimada H, Stram DO, Chatten J, Joshi VV, Hachitanda Y, Brodeur GM, Lukens JN, Matthay KK, Seeger RC.

J Natl Cancer Inst. 1995 Oct 4;87(19):1470-6.

PMID:
7674334
19.

Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.

Oberthuer A, Kaderali L, Kahlert Y, Hero B, Westermann F, Berthold F, Brors B, Eils R, Fischer M.

Clin Cancer Res. 2008 Oct 15;14(20):6590-601. doi: 10.1158/1078-0432.CCR-07-4377.

20.

Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas.

Suzuki T, Bogenmann E, Shimada H, Stram D, Seeger RC.

J Natl Cancer Inst. 1993 Mar 3;85(5):377-84.

PMID:
8433391

Supplemental Content

Support Center